1.指南来源（Guide Source）: NCCN临床实践指南:外阴癌 V4.2024.发布已获NCCN肿瘤学临床实践指南(NCCN指南®)许可。©2024美国国家综合癌症网络公司.保留所有权利。未经NCCN明确的书面许可，不得出于任何目的以任何形式复制NCCN指南®和文中的插图。要查看NCCN指南的最新完整版本，请访问NCCN.org。NCCN指南是一项持续进行的工作，可能会随着新的重要数据的出现而不断完善。  2.免责声明（Disclaimers）： NCCN对其内容、使用或应用不做任何形式的担保，并否认以任何方式对其应用或使用承担任何责任。 在下载本篇指南前，请先您详细阅读并同意以下协议： NCCN内容不得用于商业目的，以及NCCN作为NCCN内容的许可方，不作任何陈述或保证，并明确否认NCCN指南适用于任何特定患者的护理或治疗，任何医院、寻求使用《NCCN指南》治疗患者的临床医生或其他医疗服务提供者(“提供者”)应根据特定患者护理或治疗的具体临床情况做出独立的医疗判断，NCCN不建议、推荐或认可任何提供者(无论是否与被许可方相关)进行任何有偿或无偿的医疗治疗、咨询或服务，也不应因被许可方建议、推荐或认可任何此类提供者的作为或不作为而直接或间接承担责任。详见《NCCN最终用户许可协议》 3.专家名单（Staff）： *Nadeem R. Abu-Rustum, MD Ω/Chair Memorial Sloan Kettering Cancer Center *Catheryn M. Yashar, MD §/Vice Chair UC San Diego Moores Cancer Center Kristin Bradley, MD § University of Wisconsin Carbone Cancer Center Rebecca Brooks, MD Ω UC Davis Comprehensive Cancer Center Susana M. Campos, MD, MPH, MS † Dana-Farber/Brigham and Women’s Cancer Center Junzo Chino, MD § Duke Cancer Institute Hye Sook Chon, MD Ω Moffitt Cancer Center Christina Chu, MD Ω Fox Chase Cancer Center David Cohn, MD Ω The Ohio State University Comprehensive Cancer Center -James Cancer Hospital and Solove Research Institute Marta Ann Crispens, MD Ω Vanderbilt-Ingram Cancer Center Shari Damast, MD § Yale Cancer Center/Smilow Cancer Hospital Elisabeth Diver, MD Ω Stanford Cancer Institute Christine M. Fisher, MD, MPH § University of Colorado Cancer Center Peter Frederick, MD Ω Roswell Park Comprehensive Cancer Center David K. Gaffney, MD, PhD § Huntsman Cancer Institute at the University of Utah Robert Giuntoli II, MD Ω Abramson Cancer Center at the University of Pennsylvania Ernest Han, MD, PhD Ω City of Hope National Medical Center Brooke Howitt, MD ≠ Stanford Cancer Institute Warner K. Huh, MD Ω O'Neal Comprehensive Cancer Center at UAB Jayanthi Lea, MD Ω UT Southwestern Simmons Comprehensive Cancer Center Andrea Mariani, MD Ω Mayo Clinic Cancer Center David Mutch, MD Ω Siteman Cancer Center at Barnes- Jewish Hospital and Washington University School of Medicine Larissa Nekhlyudov, MD, MPH Þ Dana-Farber/Brigham and Women’s Cancer Center *Nadeem R. Abu-Rustum, MD Ω/Chair Memorial Sloan Kettering Cancer Center *Catheryn M. Yashar, MD §/Vice Chair UC San Diego Moores Cancer Center Kristin Bradley, MD § University of Wisconsin Carbone Cancer Center Rebecca Brooks, MD Ω UC Davis Comprehensive Cancer Center Susana M. Campos, MD, MPH, MS † Dana-Farber/Brigham and Women’s Cancer Center Junzo Chino, MD § Duke Cancer Institute Hye Sook Chon, MD Ω Moffitt Cancer Center Christina Chu, MD Ω Fox Chase Cancer Center David Cohn, MD Ω The Ohio State University Comprehensive Cancer Center -James Cancer Hospital and Solove Research Institute Marta Ann Crispens, MD Ω Vanderbilt-Ingram Cancer Center Shari Damast, MD § Yale Cancer Center/Smilow Cancer Hospital Elisabeth Diver, MD Ω Stanford Cancer Institute Mirna Podoll, MD ≠Vanderbilt-Ingram Cancer Center Steven W. Remmenga, MD Ω Fred & Pamela Buffett Cancer Center R. Kevin Reynolds, MD Ω University of Michigan Rogel Cancer Center Ritu Salani, MD, MBA Ω UCLA Jonsson Comprehensive Cancer Center Rachel Sisodia, MD Ω Massachusetts General Hospital Cancer Center Pamela Soliman, MD, MPH Ω The University of Texas MD Anderson Cancer Center Edward Tanner, MD Ω Robert H. Lurie Comprehensive Cancer Center of Northwestern University Stefanie Ueda, MD Ω UCSF Helen Diller Family Comprehensive Cancer Center Renata Urban, MD Ω Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance Stephanie L. Wethington, MD, MSc Ω The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Emily Wyse ¥ Patient Advocate Kristine Zanotti, MD Ω Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute NCCN Nicole McMillian, MS Angela Motter, PhD 4.临床试验（Clinical Trials）： NCCN认为任何癌症患者都可以在临床试验中得到最佳治疗，因此特别鼓励患者参与临床试验。 寻找NCCN成员组：https://www.nccn.org/home/member-institutions 5.NCCN对证据和共识分类（ NCCN Categories of Evidence and Consensus）： 推荐均为2A类，除非另有说明，请参见下表：     NCCN 对证据和共识的分类  1类  基于高水平证据，NCCN一致认为此项治疗合理  2A类  基于低水平证据，NCCN一致认为此项治疗合理  2B类  基于低水平证据，NCCN基本认为此项治疗合理  3类  基于任何水平证据，NCCN对此项治疗是否合理存在重大分歧  6.NCCN首选分类（ NCCN Categories of Preference）： 所有建议均视为合理，请参见下表：    NCCN 优先使用分类  首选干预方法  若合适，可负担，则基于疗效、安全性和证据更优的干预方法  推荐的其他干预方法  其他繁育方法可能疗效较低，毒性更多，或一句的数据不太成熟；或者具有相似疗效，但费用明显较高  某些情况下有用  其他干预方法可能会用于选定的患者人群（根据推荐类型定义）